212 related articles for article (PubMed ID: 30557833)
1. Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol.
Xu K; Liu S; Zhao X; Zhang X; Fu X; Zhou Y; Xu K; Miao L; Li Z; Li Y; Qiao L; Bao J
Biomed Pharmacother; 2019 Feb; 110():844-849. PubMed ID: 30557833
[TBL] [Abstract][Full Text] [Related]
2. Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study.
Xu K; Zhao X; Fu X; Xu K; Li Z; Miao L; Li Y; Cai Z; Qiao L; Bao J
Biomed Pharmacother; 2019 Sep; 117():109158. PubMed ID: 31252266
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol Ameliorates Lipid Droplet Accumulation in Liver Through a SIRT1/ ATF6-Dependent Mechanism.
Zhou R; Yi L; Ye X; Zeng X; Liu K; Qin Y; Zhang Q; Mi M
Cell Physiol Biochem; 2018; 51(5):2397-2420. PubMed ID: 30537742
[TBL] [Abstract][Full Text] [Related]
4. The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease.
Teng W; Zhao L; Yang S; Zhang C; Liu M; Luo J; Jin J; Zhang M; Bao C; Li D; Xiong W; Li Y; Ren F
J Control Release; 2019 Aug; 307():139-149. PubMed ID: 31233775
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation.
Badi RM; Mostafa DG; Khaleel EF; Satti HH
Clin Exp Pharmacol Physiol; 2019 Jun; 46(6):545-555. PubMed ID: 30773673
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system.
Tiao MM; Lin YJ; Yu HR; Sheen JM; Lin IC; Lai YJ; Tain YL; Huang LT; Tsai CC
Lipids Health Dis; 2018 Jul; 17(1):178. PubMed ID: 30055626
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease.
Zeng W; Shan W; Gao L; Gao D; Hu Y; Wang G; Zhang N; Li Z; Tian X; Xu W; Peng J; Ma X; Yao J
Sci Rep; 2015 Nov; 5():16013. PubMed ID: 26525891
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation.
Andrade JM; Paraíso AF; de Oliveira MV; Martins AM; Neto JF; Guimarães AL; de Paula AM; Qureshi M; Santos SH
Nutrition; 2014; 30(7-8):915-9. PubMed ID: 24985011
[TBL] [Abstract][Full Text] [Related]
9. Effects of combined therapy with resveratrol, continuous and interval exercises on apoptosis, oxidative stress, and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty liver disease.
Hajighasem A; Farzanegi P; Mazaheri Z
Arch Physiol Biochem; 2019 May; 125(2):142-149. PubMed ID: 29463133
[TBL] [Abstract][Full Text] [Related]
10. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
11. Effect of resveratrol on experimental non-alcoholic steatohepatitis.
Heebøll S; Thomsen KL; Clouston A; Sundelin EI; Radko Y; Christensen LP; Ramezani-Moghadam M; Kreutzfeldt M; Pedersen SB; Jessen N; Hebbard L; George J; Grønbæk H
Pharmacol Res; 2015; 95-96():34-41. PubMed ID: 25814186
[TBL] [Abstract][Full Text] [Related]
12. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
[TBL] [Abstract][Full Text] [Related]
13. A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
Ezhilarasan D; Lakshmi T
Oxid Med Cell Longev; 2022; 2022():9233650. PubMed ID: 35602098
[TBL] [Abstract][Full Text] [Related]
14. Effect of nuclear factor-κB and angiotensin II receptor type 1 on the pathogenesis of rat non-alcoholic fatty liver disease.
Tan DY; Shi HY; Li CP; Zhong XL; Kang M
World J Gastroenterol; 2015 May; 21(19):5877-83. PubMed ID: 26019451
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats.
Ding S; Jiang J; Zhang G; Bu Y; Zhang G; Zhao X
PLoS One; 2017; 12(8):e0183541. PubMed ID: 28817690
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver.
Tian Y; Ma J; Wang W; Zhang L; Xu J; Wang K; Li D
Mol Cell Biochem; 2016 Nov; 422(1-2):75-84. PubMed ID: 27613163
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease.
Li L; Hai J; Li Z; Zhang Y; Peng H; Li K; Weng X
Food Chem Toxicol; 2014 Jan; 63():166-73. PubMed ID: 23978414
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats.
Ma Z; Chu L; Liu H; Wang W; Li J; Yao W; Yi J; Gao Y
Sci Rep; 2017 Mar; 7():44819. PubMed ID: 28300221
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis.
BinMowyna MN; AlFaris NA; Al-Sanea EA; AlTamimi JZ; Aldayel TS
Arch Physiol Biochem; 2024 Jun; 130(3):300-315. PubMed ID: 35254877
[TBL] [Abstract][Full Text] [Related]
20. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Faghihzadeh F; Adibi P; Hekmatdoost A
Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
